Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer
Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer
About this item
Full title
Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2018-11, Vol.379 (22), p.2176-2177
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Some patients have immediate hypersensitivity responses to olaparib therapy. A gradual increase in oral doses over a 2-day period was successful at desensitization.
Alternative Titles
Full title
Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2139155790
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2139155790
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1810168
